Reoviruses

Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

Retrieved on: 
Tuesday, June 23, 2020
Clinical medicine, Medicine, Drugs, Cancer treatments, Breakthrough therapy, Merck, Immune system, Pelareorep, Reoviruses, Avelumab, Paclitaxel, Checkpoint inhibitor

Participants in the study receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with paclitaxel and Merck KGaA, Darmstadt, Germany and Pfizer's anti-PD-L1 checkpoint inhibitor, avelumab (Bavencio).

Key Points: 
  • Participants in the study receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with paclitaxel and Merck KGaA, Darmstadt, Germany and Pfizer's anti-PD-L1 checkpoint inhibitor, avelumab (Bavencio).
  • The ability of pelareorep-induced immune responses to enhance anti- PD-L1 therapy will also be evaluated through the inclusion of the paclitaxel-pelareorep-avelumab combination therapy cohort.
  • The BRACELET-1(BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti- PD-L1 and Paclitaxel) study is an open-label, phase 2, randomized study in patients with HR+/HER2-, endocrine-refractory metastatic breast cancer being conducted under a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer.
  • Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting

Retrieved on: 
Tuesday, May 26, 2020
RTT, Virotherapy, Clinical medicine, Medicine, Pelareorep, Reoviruses, Cancer, Atezolizumab, Metastatic breast cancer, Breast cancer, Oncolytic virus, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study.
  • The AWARE-1 study combines the appropriate intervention for each patient's breast cancer sub-type, pluspelareorep, with or withoutatezolizumab(Tecentriq), followed by surgery in early-stage breast cancer patients.
  • This initial data demonstrates that pelareorep treatment primes an adaptive immune response, supporting the observed survival benefit in the previous randomized phase two study in metastatic breast cancer patients.
  • We expect final data from AWARE-1 to provide mechanistic proof of concept for pelareorep and support our registration pathway."

Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting

Retrieved on: 
Tuesday, May 26, 2020
RTT, Virotherapy, Clinical medicine, Medicine, Pelareorep, Reoviruses, Cancer, Atezolizumab, Metastatic breast cancer, Breast cancer, Oncolytic virus, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study.
  • The AWARE-1 study combines the appropriate intervention for each patient's breast cancer sub-type, pluspelareorep, with or withoutatezolizumab(Tecentriq), followed by surgery in early-stage breast cancer patients.
  • This initial data demonstrates that pelareorep treatment primes an adaptive immune response, supporting the observed survival benefit in the previous randomized phase two study in metastatic breast cancer patients.
  • We expect final data from AWARE-1 to provide mechanistic proof of concept for pelareorep and support our registration pathway."

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Retrieved on: 
Friday, May 8, 2020
Virotherapy, Pelareorep, Reoviruses, System for Electronic Document Analysis and Retrieval, Oncolytic virus, Sedar, Oncolytics Biotech

For more details on the matters covered at the annual meeting please refer to the Corporation's management information circular available on SEDAR at www.sedar.com .

Key Points: 
  • For more details on the matters covered at the annual meeting please refer to the Corporation's management information circular available on SEDAR at www.sedar.com .
  • Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Retrieved on: 
Friday, May 8, 2020
Virotherapy, Pelareorep, Reoviruses, System for Electronic Document Analysis and Retrieval, Oncolytic virus, Sedar, Oncolytics Biotech

For more details on the matters covered at the annual meeting please refer to the Corporation's management information circular available on SEDAR at www.sedar.com .

Key Points: 
  • For more details on the matters covered at the annual meeting please refer to the Corporation's management information circular available on SEDAR at www.sedar.com .
  • Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic

Retrieved on: 
Friday, April 17, 2020
Health, Articles, Pelareorep, Reoviruses, Virotherapy, Clinical research, Pharmaceutical industry, Clinical, Psychological resilience

There has been no impact on the continuity of the manufacturing ofpelareorep, and Oncolytics is fully capable of supplyingpelareorepto all ongoing clinical studies.

Key Points: 
  • There has been no impact on the continuity of the manufacturing ofpelareorep, and Oncolytics is fully capable of supplyingpelareorepto all ongoing clinical studies.
  • "However, COVID-19 is severely impacting global healthcare systems, and all companies are seeking adaptations to maintain aggressive clinical activities.
  • "The resilience and dedication of our own clinical team and our collaborators is inspiring," said Dr. Rita Laeufle, Chief Medical Officer at Oncolytics.
  • "We now have all twenty clinical trial sites selected for BRACELET-1, and we are expanding the number of clinical trial sites for our AWARE-1 trial.

Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic

Retrieved on: 
Friday, April 17, 2020
Health, Articles, Pelareorep, Reoviruses, Virotherapy, Clinical research, Pharmaceutical industry, Clinical, Psychological resilience

There has been no impact on the continuity of the manufacturing ofpelareorep, and Oncolytics is fully capable of supplyingpelareorepto all ongoing clinical studies.

Key Points: 
  • There has been no impact on the continuity of the manufacturing ofpelareorep, and Oncolytics is fully capable of supplyingpelareorepto all ongoing clinical studies.
  • "However, COVID-19 is severely impacting global healthcare systems, and all companies are seeking adaptations to maintain aggressive clinical activities.
  • "The resilience and dedication of our own clinical team and our collaborators is inspiring," said Dr. Rita Laeufle, Chief Medical Officer at Oncolytics.
  • "We now have all twenty clinical trial sites selected for BRACELET-1, and we are expanding the number of clinical trial sites for our AWARE-1 trial.

Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

Retrieved on: 
Wednesday, January 22, 2020
Virotherapy, Pelareorep, Reoviruses, Medicine, Clinical medicine, Oncolytics Biotech, Medical specialties, Cancer immunotherapy, Oncolytic virus, Immune checkpoint

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning "cold" tumors "hot" - through innate and adaptive immune responses to treat a variety of cancers.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

Retrieved on: 
Wednesday, January 22, 2020
Virotherapy, Pelareorep, Reoviruses, Medicine, Clinical medicine, Oncolytics Biotech, Medical specialties, Cancer immunotherapy, Oncolytic virus, Immune checkpoint

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning "cold" tumors "hot" - through innate and adaptive immune responses to treat a variety of cancers.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

Retrieved on: 
Thursday, January 9, 2020
Branches of biology, Oncolytics Biotech, Virotherapy, Reoviruses, Pelareorep, Proteasome inhibitor, Multiple myeloma, Proteasome, Oncolytic virus

SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients.

Key Points: 
  • SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients.
  • The call, "Proteasome Inhibitors Augment Pelareorep in Multiple Myeloma" will feature Dr. Flavia Pichiorri Ph.D. and Dr. Craig Hofmeister M.D., both of whom are working on ongoing multiple myeloma studies with Oncolytics' oncolytic virus, pelareorep.
  • Management plans to provide a recap of the call next week, including key messages and insights provided by Dr. Pichiorri and Dr. Hofmeister.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.